Diagn Microbiol Infect Dis. 2016 Jul 22. pii: S0732-8893(16)30227-9. doi: 10.1016/j.diagmicrobio.2016.07.019. [Epub ahead of print]

Fluoroquinolone resistance of Streptococcus pneumoniae isolates causing invasive disease: special focus on zabofloxacin.

Kim T1, Park SJ2, Chong YP3, Park KH3, Lee YM4, Hong HL4, Kim HS2, Kim ES2, Lee S5, Choi DR6, Kim SH4, Jeong JY7, Lee SO4, Choi SH4, Woo JH4, Kim YS8.

Author information


The present study examined the in vitro activity of various antibiotics including zabofloxacin, against isolates responsible for invasive pneumococcal diseases. Between 1997 and 2008, a total of 208 isolates were collected from sterile fluids, including blood (n=196, 94.2%), pleural fluid (n=5, 2.4%), cerebrospinal fluid (n=5, 2.4%), and ascites (n=2, 1.0%). Zabofloxacin showed the lowest MIC50 (0.015μg/mL) and MIC90 (0.025μg/mL) values of all the tested antibiotics. Rates of isolates resistant to penicillin (MIC ≥8μg/mL), ceftriaxone (MIC ≥4μg/mL) and levofloxacin (MIC ≥8μg/mL) were 3.4%, 0.4% and 2.0%, respectively. Four isolates (2.0%) were resistant to levofloxacin, and zabofloxacin showed low MICs (range, 0.025-0.125μg/mL). Zabofloxacin shows potent in vitro activity against S. pneumoniae isolates that caused invasive disease, even strains that are resistant to levofloxacin.

Copyright © 2016. Published by Elsevier Inc.


Invasive; Resistance; Streptococcus pneumoniae; Zabofloxacin

PMID: 27498611 DOI: 10.1016/j.diagmicrobio.2016.07.019

[PubMed - as supplied by publisher]